Cypress says mirtazapine fails pilot trials for obstructive sleep apnea

New York, June 27 - Cypress Bioscience Inc. said a recently completed phase 2a trial of mirtazapine for obstructive sleep apnea does not support further development.

Cypress and Organon, the human healthcare business unit of Akzo Nobel, each independently conducted phase 2 trials.

A previous conducted small preliminary investigator-sponsored pilot trial found mirtazapine reduced the number of abnormal respiratory events over the course of the night by roughly 50% - but that finding was not replicated in the phase 2 trials.

Cypress is a San Diego-based company working on compounds active in the central nervous system.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.